Abstract
ctDNA is validated across multiple indications for identification of actionable mutations and detection of minimal residual disease. We evaluated if TARgeted DIgital Sequencing (TARDIS) may distinguish PR from CR with in mRCC patients (pts) receiving immune checkpoint inhibitor (ICI) therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
